

Research article

Open Access

## $\beta$ 3-adrenergic receptor gene, body mass index, bone mineral density and fracture risk in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES)

Claire Y Wang<sup>†1</sup>, Nguyen D Nguyen<sup>†1</sup>, Nigel A Morrison<sup>3</sup>, John A Eisman<sup>1,2</sup>, Jacqueline R Center<sup>1</sup> and Tuan V Nguyen<sup>\*1,2</sup>

Address: <sup>1</sup>Bone and Mineral Research Program, Garvan Institute of Medical Research, St Vincent's Hospital, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia and <sup>3</sup>School of Medical Science, Griffith University, QLD, Australia

Email: Claire Y Wang - iamclairewang@hotmail.com; Nguyen D Nguyen - n.nguyen@garvan.org.au; Nigel A Morrison - n.morrison@griffith.edu.au; John A Eisman - j.eisman@garvan.org.au; Jacqueline R Center - j.center@garvan.org.au; Tuan V Nguyen\* - t.nguyen@garvan.org.au

\* Corresponding author †Equal contributors

Published: 05 July 2006

Received: 31 March 2006

BMC Medical Genetics 2006, 7:57 doi:10.1186/1471-2350-7-57

Accepted: 05 July 2006

This article is available from: <http://www.biomedcentral.com/1471-2350/7/57>

© 2006 Wang et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Recent studies have suggested that the *Arg* allele of  $\beta$ 3-adrenergic receptor (ADRB3) gene is associated with body mass index (BMI), which is an important predictor of bone mineral density (BMD) and fracture risk. However, whether the ADRB3 gene polymorphism is associated with fracture risk has not been investigated. The aim of study was to examine the inter-relationships between ADRB3 gene polymorphisms, BMI, BMD and fracture risk in elderly Caucasians.

**Methods:** Genotypes of the ADRB3 gene were determined in 265 men and 446 women aged 60+ in 1989 at entry into the study, whose BMD were measured by DXA (GE Lunar, WI USA) at baseline. During the follow-up period (between 1989 and 2004), fractures were ascertained by reviewing radiography reports and personal interviews.

**Results:** The allelic frequencies of the *Trp* and the *Arg* alleles were 0.925 and 0.075 respectively, and the relative frequencies of genotypes *Trp/Trp*, *Trp/Arg* and *Arg/Arg* 0.857, 0.138 and 0.006 respectively. There was no significant association between BMI and ADRB3 genotypes ( $p = 0.10$  in women and  $p = 0.68$  in men). There was also no significant association between ADRB3 genotypes and lumbar spine or femoral neck BMD in either men and women. Furthermore, there were no significant association between ADRB3 genotypes and fracture risk in both women and men, either before or after adjusting for and, BMD and BMI.

**Conclusion:** The present data suggested that in Caucasian population the contribution of ADRB3 genotypes to the prediction of BMI, BMD and fracture risk is limited.

## Background

Osteoporosis and obesity are two common disorders that affect a large number of elderly in the general population [1-3]. Approximately 30% of women and 12% of men are affected by osteoporosis or low bone mass at some point during life [4]. Moreover, about 31% of elderly men and 35% of elderly women are classified as having obesity in the US [5]. Several lines of epidemiologic evidence suggest that the two disorders may be inversely associated, with obese individuals having higher bone mineral density (BMD) and reduced risk of fracture than non-obese individuals [6-11]. Indeed, it has been well-known that between 23% and 47% variance of BMD in the general population can be "explained" by the variation in body mass index (BMI) [12,13], making BMI one of the most robust and consistent predictors of BMD [14]. Both body weight (or BMI) and BMD are partly genetically determined. Twin studies have suggested that genetic factors may account for up to 80% of the BMD variance [15-17]. Likewise, between 43 to 70% of BMI variance is attributable to genetic factors [18,19]. Under the hypothesis of shared genetic effects, a gene that is associated with BMI may also protect against osteoporosis.

The variation in BMD is mainly attributable to genetic factors [16,17,20] and the liability to osteoporotic fracture is also partly determined by genetic factor [21-23]. Experimental evidence suggested that  $\beta$ 3-adrenergic stimulation can induce expression of osteoclast differentiation factor in osteoblast cells, leading to a stimulation of osteoclastogenesis [24]. Moreover, the activation of  $\beta$ 3-adrenergic receptors on two osteoblast-like cells can cause bone resorption in intact mouse calvariae [25]. In epidemiological studies, the  $\beta$ 3-adrenergic receptor (ADRB3) polymorphisms have been found to be associated with BMI [26] and BMD [27]. However, such associations, while largely found in the Japanese population, have not been well studied in Caucasian populations. Moreover, the association between ADRB3 polymorphisms and fracture risk, the ultimate outcome of osteoporosis has not been reported. The present study was aimed at examining the inter-relationships between ADRB3 gene polymorphisms, body mass index, bone mineral density and fracture risk in a well-defined sample of elderly Caucasians.

## Methods

### Study design and setting

The present study was part of the Dubbo Osteoporosis Epidemiology Study (DOES), of which the details of study design and protocols have been described previously [28-30]. Briefly, DOES is a community-based, epidemiological study, where participants were recruited from the Dubbo city, a semi-urban city 400 km northwest of Sydney, Australia, with a population of approximately 32 000 people, 98.6% Caucasian, of whom 1 581 men and 2 095

women were aged 60 years or above in 1989. Dubbo's relative isolation in terms of medical care allows virtually complete ascertainment of all fractures. From 1993, blood samples were collected from individuals who volunteer to donate at initial visits or follow-up visits. Our present study reports data on a random sample of 446 women and 265 men aged 60 years or above in 1989, who had consented to donate blood for DNA analysis.

### Measurements

After obtaining written informed consent, participants were interviewed by a trained research nurse at initial and subsequent visits at approximately 2-year intervals. A structured questionnaire was used to collect data including age, anthropometric variables, life style and clinical data [31]. Bone mineral density ( $\text{g}/\text{cm}^2$ ) was measured at the lumbar spine and femoral neck by dual-energy X-ray absorptiometry (DXA) using a Lunar DPX-L densitometer (GE Lunar, WI, USA). The measurement was performed at the same visit or within one month of the blood sample collection in 99% of cases. In the cases in which the blood was taken at a time other than the scheduled visit, the BMD used was that closest to the time of blood collection.

### Ascertainment of fracture

The incidence of fracture was ascertained during the study period (1989-2004) by radiologist's report and confirmed by personal interview. Only low trauma fractures were included (i.e. a fall from the standing height or less). Fractures due to motor vehicle accidents or pathological conditions were excluded. Fractures were categorised into 4 groups: hip, symptomatic vertebral, Colles' and other fractures.

### Genotyping

Genomic DNA was extracted from peripheral blood leukocytes. The ADRB3 polymorphism was determined by polymerase chain reaction (PCR) performed with 20 ng of genomic DNA with upstream primer 5' CCA GTG GGC TGC CGA GGG 3' and downstream primer 5' GCC AGT GGC GCC CAA CGG 3' [32]. The amplification products were digested with the restriction enzyme *Bst*OI (Promega, Madison, WI, USA) and genotyped as *Trp* homozygotes (*Trp/Trp*), heterozygotes (*Trp/Arg*), or *Arg* homozygotes (*Arg/Arg*). This *Trp*<sup>64</sup>*Arg* polymorphism has been commonly used in genetic epidemiological studies.

### Statistical analysis

Alleles were counted and the genotype frequencies of the polymorphism was checked for Hardy-Weinberg equilibrium (HWE) by the likelihood Chi-square statistic [33]. The baseline characteristics of the subjects in the fracture group and the non-fracture group were compared using descriptive statistical tests with appropriate techniques (e.g. Student's t-test for normally distributed variables,

such as BMI and BMD) and Chi-square (for categorical data), depends on the distribution of the variables. The association between each polymorphism and BMD or BMI was analyzed by the analysis of covariance (ANCOVA) model taking into account the effects of potential covariates such as age, weight and life-style factors.

In order to quantify the risk of sustaining a fracture in relation to ADRB3 genotypes, subjects were grouped into those with *Arg* allele and those without *Arg* allele. The association was analyzed by the logistic regression model taking into account the effects of potential confounders.

In order to determine the association between BMI and ADRB3 polymorphisms, a Bayesian approach was used [34,35]. In the Bayesian analysis, the currently observed data are combined with known data to derive a "posterior distribution" with credible interval. In the present study, a prior mean difference ( $M_0$ ) in BMI between subjects with and without *Arg* allele was obtained from a meta-analysis [26] with a 95% confidence interval (95%CI) being ( $L_0$ ,  $U_0$ ), from which the standard deviation ( $SD_0$ ) for the prior distribution was calculated as follow:  $SD_0 = (U_0 - L_0) / 3.92$ , assuming the difference follows the normal distribution. In order to construct a posterior distribution with mean ( $M_p$ ) and standard deviation ( $SD_p$ ), the prior distribution was combined with the present study's data, which has a mean of  $M_d$  and standard deviation of  $SD_d$ . The posterior mean and SD are:  $M_p = (SD_p)^2 [(M_0/SD_0^2) + (M_d/SD_d^2)]$  and  $SD_p = 1 / \sqrt{(1/SD_0^2) + (1/SD_d^2)}$ . Thus, the posterior mean is a weighted average of two estimates (prior mean and the present study's mean) with the weight being the inverse variances. The analysis was conducted via the SAS system [36].

## Results

### Characteristics of study subjects

In total, 446 women and 265 men who had been followed-up for the median of 13.2 years (interquartile range, IQR: 10.4–14.1) and 12.9 years (IQR: 9.0–14.0) for women and men, respectively.

The frequencies of the *Trp/Trp*, *Trp/Arg* and *Arg/Arg* genotypes were 385 (86.3%), 58 (13.0%) and 3 (0.7%) respectively for women, and 224 (84.5), 40 (15.1%) and 1 (0.4%) respectively for men. In both sexes, the allelic frequencies of *Trp* allele and *Arg* allele were 0.925 and 0.075 respectively. Because the frequency of *Arg* allele was low in the population, individuals with *Trp/Arg* and *Arg/Arg* genotypes were considered as one group. The overall geno-

type distribution in the study subjects was in Hardy-Weinberg equilibrium ( $\chi^2 = 0.007$ ,  $p = 0.98$ ).

Clinical characteristics of subjects were stratified by the presence or absence of *Arg* allele (Table 1). The presence of *Arg* allele in women is associated with a 0.25 SD increase in body weight, but this difference was not statistically significant ( $p = 0.08$ ). In both women and men, there were no statistically significant differences between *Arg* allele carriers and non-carriers in terms of anthropometric characteristics and lifestyle factors.

### ADRB3 genotypes and BMI

In the present study, there was no significant association between ADRB3 genotypes and BMI. The overall mean difference in BMI for *Arg* carriers versus non-carriers was 0.54 kg/m<sup>2</sup> (95% CI: -0.35, 1.44;  $P = 0.23$ ), or 0.13 SD. In a previous meta-analysis [26], *Arg* carriers had higher BMI than non-*Arg* carriers by 0.30 (95% CI, 0.13–0.47) kg/m<sup>2</sup> as indicated in the prior distribution (Figure 1). After updating the previous data with the present study's data, the posterior distribution showed that BMI in the *Arg* allele carriers are, on average, 0.31 kg/m<sup>2</sup> (95% CI, 0.14–0.48) higher than non-*Arg* carriers.

### ADRB3 genotypes and BMD

In multiple regression analysis of BMD measurements at both lumbar spine and femoral neck (Table 2), there were no significant associations between ADRB3 and BMD at both LS and FN sites. However, in both women and men, age and smoking history were negatively associated with femoral neck BMD, and BMI was positively associated with lumbar spine and femoral neck BMD. Although increased physical activity was not associated with BMD measured at femoral neck, it was positively associated with lumbar spine BMD. Collectively these factors (age, BMI, smoking history, calcium intake, physical activity and ADRB3 genotypes) explained about 30% and 12% of variances in femoral neck BMD in women and men respectively.

### ADRB3 genotypes and fracture risk

During the follow up period, 173 women and 49 men had sustained at least one osteoporotic fracture. In women, the most common fracture site was distal radius (Colles' fracture) with an incidence rate of 24% of all the cases, followed by vertebral (23%) and hip (14%). In men, the most common fracture site was vertebrae (41%), followed by hip (16%) and ribs (14%). For both women and men, fracture individuals were older, weighed less, and had lower BMD at both femoral neck and lumbar spine compared to their non-fracture counterparts (Table 3). However, there was no significant difference between the fracture group and non-fracture group in terms of calcium intake, physical activity and smoking history.

**Table 1: Baseline characteristics of subjects stratified by ADRB3 genotype**

	Trp/Trp	Trp/Arg + Arg/Arg	Standardized difference	P value
<b>Women (N)</b>	385	61		
Age (y)	71 ± 8	71 ± 6	0.00	0.47
Weight (kg)	64 ± 12	67 ± 13	0.25	0.08
Height (cm)	160 ± 6	160 ± 6	0.00	0.90
BMI (kg/m <sup>2</sup> )	25 ± 5	26 ± 5	0.20	0.10
Ca intake (mg/day)	644 ± 372	650 ± 355	0.02	0.90
Physical activity (METs)	80 ± 30	82 ± 23	0.07	0.54
Femoral neck BMD (g/cm <sup>2</sup> )	0.76 ± 0.13	0.79 ± 0.13	0.23	0.24
Lumbar spine BMD (g/cm <sup>2</sup> )	1.00 ± 0.18	1.04 ± 0.21	0.22	0.11
Age of menopause (y)	47 ± 7	46 ± 7	-0.14	0.52
Current/ex smoker <sup>a,b</sup>	106 (27.5)	22 (36.1)		1.87
<b>Men (N)</b>	224	41		
Age (y)	70 ± 6	68 ± 5	-0.34	0.12
Weight (kg)	78 ± 12	77 ± 13	-0.08	0.46
Height (cm)	174 ± 6	173 ± 8	-0.16	0.77
BMI (kg/m <sup>2</sup> )	26 ± 3	26 ± 4	0.00	0.68
Ca intake (mg/day)	657 ± 367	732 ± 317	0.21	0.23
Physical activity (METs)	76 ± 49	72 ± 48	-0.08	0.69
Femoral neck BMD (g/cm <sup>2</sup> )	0.92 ± 0.15	0.93 ± 0.15	0.07	0.63
Lumbar spine BMD (g/cm <sup>2</sup> )	1.26 ± 0.21	1.24 ± 0.24	-0.09	0.59
Current/ex smoker <sup>a,b</sup>	122 (54.5)	25 (61.0)		0.59

Values are mean ± SD, otherwise specified; P values were calculated using unpaired t-test, otherwise specified. BMI, body mass index; Ca, calcium; METs, metabolic equivalents.

<sup>a</sup> N(%); <sup>b</sup> Chi-square test.

The distribution of ADRB3 genotypes in fracture and non-fracture subjects is shown in Table 4. Women with the *Arg/Arg* and *Trp/Arg* genotypes had lower incident rate of any fracture than those with the *Trp/Trp* genotype, but the difference was not statistically significant (32.8% vs. 39.7%,  $p = 0.30$ ). This non-significant association was observed for all specific fracture sites. However, in men, individuals with the *Arg/Arg* and *Trp/Arg* genotypes had higher incident rate of any fracture than those with the *Trp/Trp* genotype (22.0% vs. 17.9%); the difference was also not statistically significant ( $p = 0.53$ ). After adjusting for age, BMI and/or BMD, the associations between the ADRB3 polymorphism and fracture risk in women and men were not statistically significant (Table 5). There were no interaction effects between ADRB3 genotypes and age on fracture risk (data not shown).

## Discussion


Obesity is associated with increased BMD and reduced fracture risk [11,37]. Studies on polymorphisms of the ADRB3 gene and their association with BMD have been reported in the Japanese population [27,38], but not in Caucasians. The present data further suggested that there was no significant association between ADRB3 genotypes and fracture risk in a Caucasian population.

The ADRB3 genotypes have largely been investigated for association with BMI in the Japanese population, from

whom a significant association has been reported. The association was characterised by individuals with the *Arg* allele having higher BMI than individuals without the *Arg* allele. In this study, individuals with the *Arg* allele also had higher BMI than individuals without the *Arg* allele, but the difference did not reach statistical significance. Nevertheless, by using the Bayesian approach (i.e., updating the current data with previous data) it was found that there was a 99% probability that BMI among those with the *Arg* allele was higher than those without the *Arg* allele.

The frequency of the *Arg* allele in the present study was similar to that reported for the Australian population [39] and other Caucasian populations [40,41], but lower than that of Asian populations [27,42-44]. To our knowledge, the present study is the first to investigate the association between ADRB3 genotypes and BMD and fracture risk in Caucasian population.

The present results suggest there was no statistically significant association between ADRB3 genotypes and BMD. This is consistent with previous findings in Japanese women [27,38] (Table 6). It has been suggested that the association between ADRB3 and BMD are more likely to be found in obese individuals than in non-obese individuals. However, in the present study, the non-significant association between ADRB3 and BMD was observed in both obese and non-obese individuals (data not shown).



**Figure 1**  
Posterior distribution of mean difference in BMI (kg/m<sup>2</sup>) between Arg carriers and non-Arg carriers.

In this current study, no significant association was observed in either sex. However, while women with the Arg allele appeared to have lower risk of fracture, men with the Arg allele had increased risk of fracture. The reason for this opposite trend was not apparent; however, stochastic fluctuation can be a contributory factor.

BMD is largely determined by genetic factors [45], and as BMI is a strong predictor of BMD [14], we thus hypothesized that ADRB3, being a candidate gene for BMI, would have pleiotropic effect on both BMD and BMI. However, the present results did not support the hypothesis, and the effect of ADRB3 seemed to be BMI specific, and the effect of ADRB3 on BMI showed a 0.31 kg/m<sup>2</sup> difference between genotypes.

The present study was based on a relatively large sample size which has been followed up for a reasonably long period of time (up to 15 years), which allows more precise

delineation of effect than smaller studies. Moreover, subjects in this study are of Caucasian background, and the present results are likely to be valid in similar populations of elderly Caucasians. However, a potential limitation is that with the low prevalence of the Arg allele in the ADRB3 gene there are small numbers of subjects with the Arg/Arg genotype. Since fracture is a relatively rare event, the lack of fracture cases in individuals with Arg allele could limit the power of the study.

Furthermore, this study examined only one polymorphism which may not adequately capture the polymorphic variation within the gene, and hence limited the chance of finding an underlying association. There is also a lack of association studies investigating the relationship between ADRB3 genotypes and BMD, and no studies have investigated the association between ADRB3 genotypes and fracture risk, therefore no prior information could be drawn to reinforce our findings via the Bayesian approach.

**Conclusion**

In summary, the present data suggested that in elderly men and women, there is a weak positive association between Arg allele of the ADRB3 gene and BMI. However, no significant associations were observed between ADRB3 polymorphisms and BMD or fracture risk, and it seems unlikely that ADRB3 has a significant predictive value for osteoporotic fracture risk.

**Abbreviations**

All abbreviations are defined in the text.

**Competing interests**

Dr John Eisman who serves as a consultant and receives corporate appointment from Aventis, Eli Lilly and Company, Merck Sharp & Dohme Ltd., Novartis, MPS Pharmaceuticals, Organon, Roche and Servier.

All other authors have neither financial nor non-financial competing interests that may be affected from the publication of the manuscript.

**Authors' contributions**

CYW and NDN obtained and analysed data, and drafted the manuscript. NM performed the genotyping and was initially involved in the conceptual discussion of the project. JRC had an active role in the conduct of the Dubbo Osteoporosis Epidemiology Study. JAE established the Dubbo Osteoporosis Epidemiology Study. TVN had an active role in the Dubbo Osteoporosis Epidemiology Study since its inception; he was involved in the study design, data analysis, and in the conceptual discussion of the project. All authors contributed to the last version of the manuscript.

**Table 2: ADRB3 genotype and BMD: Standardized regression coefficient from the multiple regression analyses**

	LSBMD		FNBMD	
	Coefficient	P value	Coefficient	P value
<b>Women</b>				
Age	-0.040	0.380	-0.344	<0.01
BMI	0.366	<0.01	0.382	<0.01
Smoking	-0.041	0.37	-0.087	0.03
Calcium intake	-0.018	0.69	0.050	0.23
Physical activity	0.140	<0.01	0.035	0.40
ADRB3 <sup>a</sup>	0.044	0.33	0.046	0.26
R <sup>2</sup>	0.162		0.302	
<b>Men</b>				
Age	-0.018	0.78	-0.187	<0.01
BMI	0.231	<0.01	0.240	<0.01
Smoking	-0.104	0.09	-0.149	<0.01
Calcium intake	0.091	0.14	0.048	0.01
Physical activity	0.124	0.05	0.036	0.43
ADRB3 <sup>a</sup>	0.001	0.99	0.003	0.60
R <sup>2</sup>	0.074		0.120	

LSBMD, lumbar spine bone mineral density; FNBMD, femoral neck bone mineral density.

R<sup>2</sup>: coefficient of determination; proportion of variance of BMD (LSBMD or FNBMD) accounted for by all the factors in the model. <sup>a</sup>Non-Arg allele carrier and Arg allele carrier.

**Table 3: Baseline characteristics of subjects with and without fracture**

	Any fracture	Non-fracture	Mean difference (95% CI)	SD <sup>a</sup>	P value
<b>Women</b>					
Number of subjects	173	273			
Age (y)	72 ± 8	70 ± 7	1.86 (0.46, 3.226)	0.27	<0.01
Weight (kg)	63 ± 12	66 ± 12	-2.76 (-5.14, -0.38)	-0.25	0.03
Height (cm)	159 ± 7	160 ± 6	-0.89 (-2.06, 0.27)	-0.16	0.13
BMI (kg/m <sup>2</sup> )	25 ± 4	26 ± 5	-0.88 (-1.76, 0)	-0.22	0.05
Ca intake (mg/day)	640 ± 379	648 ± 364	-7.70 (-78.93, 63.52)	-0.02	0.83
Physical activity (METs)	83 ± 32	79 ± 27	3.67 (-1.99, 9.32)	0.14	0.20
Femoral neck BMD (g/cm <sup>2</sup> )	0.72 ± 0.12	0.80 ± 0.13	-0.07 (-0.10, -0.05)	-0.63	<0.01
Lumbar spine BMD (g/cm <sup>2</sup> )	0.95 ± 0.17	1.04 ± 0.19	-0.09 (-0.12, -0.05)	-0.49	<0.01
Age of menopause (y)	46 ± 8	47 ± 7	-1.46 (-2.86, -0.06)	-0.14	0.04
Current/ex smoker <sup>b,c</sup>	46 (26.6)	82 (30.0)			0.43
<b>Men</b>					
Number of subjects	49	216			
Age (y)	73 ± 6	69 ± 6	3.54 (1.73, 5.36)	0.67	<0.01
Weight (kg)	75 ± 11	79 ± 12	-4.05 (-7.81, -0.29)	-0.34	0.03
Height (cm)	171 ± 7	174 ± 6	-2.75 (-4.82, -0.69)	-0.48	0.01
BMI (kg/m <sup>2</sup> )	25 ± 3	26 ± 4	-0.54 (-1.64, 0.55)	-0.26	0.33
Ca intake (mg/day)	693 ± 475	663 ± 330	29.77 (-83.66, 143.19)	0.08	0.61
Physical activity (METs)	84 ± 53	73 ± 47	11.19 (-4.59, 26.98)	0.23	0.16
Femoral neck BMD (g/cm <sup>2</sup> )	0.85 ± 0.13	0.94 ± 0.15	-0.09 (-0.14, -0.05)	-0.61	<0.01
Lumbar spine BMD (g/cm <sup>2</sup> )	1.14 ± 0.20	1.28 ± 0.21	-0.14 (-0.21, -0.07)	-0.67	<0.01
Current/ex smoker <sup>b,c</sup>	33 (67.3)	114 (52.8)			0.06

Values are mean ± SD, otherwise specified; P values are calculated using unpaired t-test, otherwise specified. BMI, body mass index; Ca, calcium; METs, metabolic equivalents;

<sup>a</sup>Standardized difference; <sup>b</sup>Chi-square test; <sup>c</sup>N(%).

**Table 4: Frequency of fracture types stratified by  $\beta$ 3-Adrenergic Receptor genotype**

	Genotype		P value <sup>a</sup>
	Trp/Trp	Arg/Arg+ Trp/Arg	
<b>Women (N)</b>	385	61	
Non-fracture	232 (60.3)	41 (67.2)	
Any fracture	153 (39.7)	20 (32.8)	0.30
Hip fracture	37 (13.8)	4 (8.9)	0.66 <sup>b</sup>
Vertebral fracture	53 (18.6)	5 (10.9)	0.23
Wrist/forearm	54 (18.9)	5 (10.9)	0.21
<b>Men (N)</b>	224	41	
Non-fracture	184 (82.1)	32 (78.1)	
Any fracture	40 (17.9)	9 (22.0)	0.53
Hip fracture	8 (4.2)	2 (5.9)	0.66 <sup>b</sup>
Vertebral fracture	17 (8.5)	5 (13.5)	0.33
Wrist/forearm	3 (1.6)	1 (3.0)	0.49 <sup>b</sup>

<sup>a</sup>Chi-square test, otherwise specified; <sup>b</sup>Fisher's exact test

**Table 5: Relationship between  $\beta$ 3-Adrenergic Receptor genotypes and fracture risk**

	Any fracture	Hip fracture	Vertebral fracture	Wrist/forearm <sup>b</sup>
<b>Women</b>				
ADRB3 unadjusted <sup>a</sup>	0.74 (0.42, 1.31)	0.66 (0.23, 1.92)	0.56 (0.21, 1.46)	0.55 (0.21, 1.43)
Adjusted for age (1)	0.72 (0.40, 1.28)	0.66 (0.22, 1.96)	0.55 (0.21, 1.43)	0.54 (0.21, 1.42)
Adjusted for FNBMD (2)	0.84 (0.46, 1.55)	0.83 (0.25, 2.77)	0.62 (0.24, 1.64)	0.61 (0.23, 1.61)
Adjusted for BMI (3)	0.76 (0.42, 1.37)	0.82 (0.27, 2.44)	0.60 (0.23, 1.56)	0.57 (0.22, 1.50)
Adjusted for (1) and (2)	0.84 (0.45, 1.55)	0.78 (0.23, 2.61)	0.60 (0.23, 1.58)	0.61 (0.23, 1.60)
Adjusted for (1) and (3)	0.74 (0.41, 1.33)	0.70 (0.23, 2.16)	0.57 (0.22, 1.51)	0.56 (0.22, 1.48)
Adjusted for (1) and (2) and (3)	0.83 (0.45, 1.53)	0.75 (0.22, 2.56)	0.60 (0.23, 1.59)	0.61 (0.23, 1.60)
<b>Men</b>				
ADRB3 unadjusted <sup>a</sup>	1.29 (0.57, 2.92)	1.39 (0.28, 6.76)	1.69 (0.59, 4.88)	1.84 (0.19, 18.18)
Adjusted for age (1)	1.57 (0.68, 3.65)	2.87 (0.50, 16.39)	2.03 (0.69, 6.02)	-
Adjusted for FNBMD (2)	1.25 (0.52, 3.04)	1.47 (0.29, 7.46)	1.88 (0.62, 5.71)	-
Adjusted for BMI (3)	1.28 (0.56, 2.89)	1.34 (0.27, 6.58)	1.66 (0.57, 4.78)	-
Adjusted for (1) and (2)	1.47 (0.60, 3.62)	3.03 (0.52, 17.54)	2.15 (0.69, 6.67)	-
Adjusted for (1) and (3)	1.57 (0.67, 3.65)	2.85 (0.50, 16.39)	2.02 (0.68, 6.02)	-
Adjusted for (1) and (2) and (3)	1.46 (0.59, 3.62)	2.88 (0.48, 7.24)	2.15 (0.69, 6.67)	-

Values are Odds ratio and 95% CI;

<sup>a</sup>Arg-allele carriers were considered the risk factor in the model and Trp/Trp genotype was the reference group.

<sup>b</sup>adjusted OR was not calculated for wrist/forearm fracture in men due to small number of fracture.

**Table 6:  $\beta$ 3AR genotypes and bone mineral density: summary of previous and present studies**

First Author and genotypes	N (%)	Femoral neck BMD (mean; SD)	Lumbar spine BMD (mean; SD)	Total body BMD (mean; SD)
Ogawa et al. [38] <sup>a</sup>				
Trp/Trp and Trp/Arg	267 (95.4)	NA	0.145 (1.36)	0.432 (0.93)
Arg/Arg	13 (4.6)	NA	0.179 (2.11)	-0.135 (0.93)
P-value		NA	NS	0.033
Kasumata et al. [27] <sup>b</sup>				
Trp/Trp and Trp/Arg	142 (97.6)	NA	NA	NA
Arg/Arg	3 (2.4)	NA	NA	NA
P-value		NS	NS	NA
The present study				
Trp/Trp	385 (86.3)	0.76 (0.13)	1.00 (0.18)	NA
Trp/Arg and Arg/Arg	61 (13.7)	0.79 (0.13)	1.04 (0.21)	NA
P-value		0.238	0.113	NA

NA, not available; NS, non-significant. <sup>a</sup>Values were shown as Z-scores BMD. <sup>b</sup>Data were not shown; the authors only stated in text: "No association was demonstrated between the ER, CaSR or  $\beta$ 3-AR genotypes and BMD, either alone or in relation to other polymorphisms".

## Acknowledgements

We gratefully acknowledge the assistance of Sr Janet Watters and Donna Reeves for the interview, data collection and measurement bone mineral density. We also appreciate the invaluable help of the staff of Dubbo base hospital. This works has been partly supported by the National Health and Medical Research Council of Australia and untied educational grants from GE-Lunar, Merck Australia, Eli Lilly International and Aventis Australia.

## References

- Flegal KM, Graubard BI, Williamson DF, Gail MH: **Excess deaths associated with underweight, overweight, and obesity.** *JAMA* 2005, **293**(15):1861-1867.
- Andreyeva T, Sturm R, Ringel JS: **Moderate and severe obesity have large differences in health care costs.** *Obes Res* 2004, **12**(12):1936-1943.
- Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ: **Obesity prevention: the case for action.** *Int J Obes Relat Metab Disord* 2002, **26**(3):425-436.
- Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N: **The diagnosis of osteoporosis.** *J Bone Miner Res* 1994, **9**(8):1137-1141.
- Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM: **Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.** *JAMA* 2004, **291**(23):2847-2850.
- Pruzansky ME, Turano M, Luckey M, Senie R: **Low body weight as a risk factor for hip fracture in both black and white women.** *J Orthop Res* 1989, **7**(2):192-197.
- Turner LW, Wang MQ, Fu Q: **Risk factors for hip fracture among southern older women.** *South Med J* 1998, **91**(6):533-540.
- del Puente A, Postiglione A, Esposito-del Puente A, Carpinelli A, Romano M, Oriente P: **Peripheral body fat has a protective role on bone mineral density in elderly women.** *Eur J Clin Nutr* 1998, **52**(9):690-693.
- Margolis KL, Ensrud KE, Schreiner PJ, Tabor HK: **Body size and risk for clinical fractures in older women. Study of Osteoporotic Fractures Research Group.** *Ann Intern Med* 2000, **133**(2):123-127.
- Shiraki M, Ito H, Fujimaki H, Higuchi T: **Relation between body size and bone mineral density with special reference to sex hormones and calcium regulating hormones in elderly females.** *Endocrinol Jpn* 1991, **38**(4):343-349.
- Nguyen ND, Pongchaiyakul C, Center JR, Eisman JA, Nguyen TV: **Abdominal fat and hip fracture risk in the elderly: The Dubbo Osteoporosis Epidemiology Study.** *BMC Musculoskelet Disord* 2005, **6**(1):11.
- Orozco P, Nolla JM: **Associations between body morphology and bone mineral density in premenopausal women.** *Eur J Epidemiol* 1997, **13**(8):919-924.
- Martinez Diaz-Guerra G, Hawkins F, Rapado A, Ruiz Diaz MA, Diaz-Curiel M: **Hormonal and anthropometric predictors of bone mass in healthy elderly men: major effect of sex hormone binding globulin, parathyroid hormone and body weight.** *Osteoporos Int* 2001, **12**(3):178-184.
- Blum M, Harris SS, Must A, Phillips SM, Rand WM, Dawson-Hughes B: **Weight and body mass index at menarche are associated with premenopausal bone mass.** *Osteoporos Int* 2001, **12**(7):588-594.
- Christian JC, Yu PL, Slemenda CW, Johnston CCJ: **Heritability of bone mass: a longitudinal study in aging male twins.** *Am J Hum Genet* 1989, **44**(3):429-433.
- Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S: **Genetic determinants of bone mass in adults. A twin study.** *J Clin Invest* 1987, **80**(3):706-710.
- Nguyen TV, Howard GM, Kelly PJ, Eisman JA: **Bone mass, lean mass, and fat mass: same genes or same environments?** *Am J Epidemiol* 1998, **147**(1):3-16.
- Nath SK, Chakravarti A, Chen CH, Cooper R, Weder A, Schork NJ: **Segregation analysis of blood pressure and body mass index in a rural US community.** *Hum Biol* 2002, **74**(1):11-23.
- Allison DB, Kaprio J, Korkeila M, Koskenvuo M, Neale MC, Hayakawa K: **The heritability of body mass index among an international sample of monozygotic twins reared apart.** *Int J Obes Relat Metab Disord* 1996, **20**(6):501-506.
- Flicker L, Hopper JL, Rodgers L, Kaymakci B, Green RM, Wark JD: **Bone density determinants in elderly women: a twin study.** *J Bone Miner Res* 1995, **10**(11):1607-1613.
- Kannus P, Palvanen M, Kaprio J, Parkkari J, Koskenvuo M: **Genetic factors and osteoporotic fractures in elderly people: prospective 25 year follow up of a nationwide cohort of elderly Finnish twins.** *Bmj* 1999, **319**(7221):1334-1337.
- Nguyen TV, Esteban LM, White CP, Grant SF, Center JR, Gardiner EM, Eisman JA: **Contribution of the collagen I alpha and vitamin D receptor genes to the risk of hip fracture in elderly women.** *J Clin Endocrinol Metab* 2005, **90**(12):6575-6579.
- Mann V, Ralston SH: **Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture.** *Bone* 2003, **32**(6):711-717.
- Takeuchi T, Tsuboi T, Arai M, Togari A: **Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells.** *Biochem Pharmacol* 2001, **61**(5):579-586.
- Moore RE, Smith CK, Bailey CS, Voelkel EF, Tashjian AHJ: **Characterization of beta-adrenergic receptors on rat and human**



- osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. *Bone Miner* 1993, **23(3)**:301-315.
26. Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T: **Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index.** *J Clin Endocrinol Metab* 1998, **83(7)**:2441-2444.
  27. Katsumata K, Nishizawa K, Unno A, Fujita Y, Tokita A: **Association of gene polymorphisms and bone density in Japanese girls.** *J Bone Miner Metab* 2002, **20(3)**:164-169.
  28. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA: **Mortality after all major types of osteoporotic fracture in men and women: an observational study.** *Lancet* 1999, **353(9156)**:878-882.
  29. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA: **Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES).** *Osteoporos Int* 1994, **4(5)**:277-282.
  30. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN: **Risk factors for osteoporotic fractures in elderly men.** *Am J Epidemiol* 1996, **144(3)**:255-263.
  31. Nguyen TV, Center JR, Eisman JA: **Osteoporosis in elderly men and women: effects of dietary calcium, physical activity, and body mass index.** *J Bone Miner Res* 2000, **15(2)**:322-331.
  32. Clement K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD: **Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity.** *N Engl J Med* 1995, **333(6)**:352-354.
  33. SPSS Inc.: **SPSS 13.0 Base User's Guide.** Chicago, IL , SPSS Inc.; 2004.
  34. Matthews RAJ: **Facts versus fictions: The use and abuse of subjectivity in scientific research: Barton, Cambridge, UK.** ; 1998.
  35. Spiegelhalter DJ, Abrams KR, Myles JP: **Bayesian Approaches to Clinical Trials and Health-Care Evaluation.** West Sussex, England , John Wiley & Sons Ltd.; 2004.
  36. SAS Institute Inc.: **Base SAS 9.1.3 Procedures Guide, Volumes 1-4.** In Base SAS 9.1.3 (TS1M3) edition. Cary, NC, USA , SAS Publishing; 2004.
  37. Leonard MB, Shults J, Wilson BA, Tershakovec AM, Zemel BS: **Obesity during childhood and adolescence augments bone mass and bone dimensions.** *Am J Clin Nutr* 2004, **80(2)**:514-523.
  38. Ogawa S, Emi M, Shiraki M, Hosoi T, Orimo H, Ouchi Y, Inoue S: **Association of amino acid variation (Trp64Arg) in the beta3-adrenergic receptor gene with bone mineral density.** *Geriatrics and Gerontology International* 2002, **2(3)**:138-142.
  39. Kurabayashi T, Carey DG, Morrison NA: **The beta 3-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Effects on weight, BMI, abdominal fat, blood pressure, and reproductive history in an elderly Australian population.** *Diabetes* 1996, **45(10)**:1358-1363.
  40. Li LS, Lonnqvist F, Luthman H, Arner P: **Phenotypic characterization of the Trp64Arg polymorphism in the beta 3-adrenergic receptor gene in normal weight and obese subjects.** *Diabetologia* 1996, **39(7)**:857-860.
  41. Oksanen L, Mustajoki P, Kaprio J, Kainulainen K, Janne O, Peltonen L, Kontula K: **Polymorphism of the beta 3-adrenergic receptor gene in morbid obesity.** *Int J Obes Relat Metab Disord* 1996, **20(12)**:1055-1061.
  42. Hao K, Peng S, Xing H, Yu Y, Huang A, Hong X, Wang Y, Chen C, Wang B, Zhang X, Liu J, Zhu G, Huo Y, Chen D, Zhao X, Ronnenberg A, Wu D, Niu T, Xu X: **beta(3) Adrenergic receptor polymorphism and obesity-related phenotypes in hypertensive patients.** *Obes Res* 2004, **12(1)**:125-130.
  43. Matsushita H, Kurabayashi T, Tomita M, Kato N, Tanaka K: **Effects of uncoupling protein 1 and beta3-adrenergic receptor gene polymorphisms on body size and serum lipid concentrations in Japanese women.** *Maturitas* 2003, **45(1)**:39-45.
  44. Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga H, Kosaka K, Yamada N, et al.: **A mutation in the beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects.** *Biochem Biophys Res Commun* 1995, **215(2)**:555-560.
  45. Livshits G, Deng HW, Nguyen TV, Yakovenko K, Recker RR, Eisman JA: **Genetics of bone mineral density: evidence for a major**

**pleiotropic effect from an intercontinental study.** *J Bone Miner Res* 2004, **19(6)**:914-923.

## Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/7/57/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

